Shengfeng founded Bio-Thera in 2003, and has served since that time as Chief Executive Officer and as a member of our Board of Directors. Prior to founding Bio-Thera, Shengfeng was a founder and founding Chief Scientific Officer of Abmaxis, Inc., California (acquired by Merck). Prior to co-founding Abmaxis, he was employed at Cor Therapeutics, (merged with Millennium). Dr. Li received his Ph.D. in Microbiology from the University of Georgia in 1991, and afterwards, he worked as a postdoctoral scientist and later as a Donoghue Foundation fellow at Yale, where he identified several Raf kinase signaling regulatory molecules such as RKIP and 14-3-3 family of proteins. Dr. Li is an author on multiple publications in peer reviewed journals such as Nature, EMBO, Gene & Dev, and PNAS. He is an inventor on over 50 patents in the areas of target identification, drug discovery, antibody engineering, and product development.